Description
Kiaresta 1 mg Neola — letrozole from Neola at 1 mg. Third-generation non-steroidal aromatase inhibitor — 2–5× more potent than anastrozole per mg. Reserved for heavy cycles or gynaecomastia reversal.
Key Benefits
- Most potent aromatase inhibitor in clinical use
- Reserved for aggressive E2 control or gyno rescue protocols
- 98%+ aromatase inhibition at standard doses
- Easy to over-suppress — titration with bloodwork essential
- Not a first-line on-cycle AI — anastrozole or exemestane preferred
- Each unit dosed at 1 mg — see Recommended Dosage below for protocol-specific intake
Recommended Dosage
Research dosing: 0.5–1.25 mg every other day for aggressive E2 management; 2.5 mg daily for 10–14 days for gyno rescue. Start low — letrozole crashes E2 fast. Bloodwork at 2 weeks mandatory.
How It Works
Non-steroidal aromatase inhibitor. Achieves ~98% aromatase inhibition at therapeutic doses (vs anastrozole ~85%). Reversible binding. Used clinically for breast cancer; off-label in AAS protocols for aggressive cycles or gyno reversal.
Pharmacokinetics
Plasma half-life approximately 2 days. Every-other-day or daily dosing depending on target. Steady-state in 10 days.
Potential Side Effects
Signature risk: crashed E2 with joint pain, libido loss, fatigue. Lipids can take a bigger hit than anastrozole. Use only when less potent AIs are insufficient.
Cycle & Stacking Guide
Reserved for aggressive E2 management or gyno rescue. Typical use: week 1–2 at 2.5 mg/day to reverse active gyno, then transition to anastrozole maintenance. Not a first-line on-cycle AI.
Manufacturer Notes
Neola produces research compounds including SERMs at standardised dosages. Batch QC documentation available.
Storage & Handling
Store at recommended temperature (15–25°C; peptides and HGH at 2–8°C after reconstitution). Protect from light and moisture. Keep out of reach of children. For research and educational purposes only.
Reviews
There are no reviews yet.